New Delhi, Feb 6 (PTI) Biocon Ltd on Tuesday said it has received approval from the US health regulator for a generic anti-cancer medication.

The company has received approval from the US Food and Drug Administration (USFDA) for Dasatinib tablets to market in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Biocon said in a regulatory filing.

Also Read | Union Bank of India Recruitment 2024: Applications Invited for 606 Specialist Officer Posts Till February 23, Apply Online at unionbankofindia.co.in.

The approval will further strengthen the company's portfolio of vertically integrated, complex drug products, it added.

Shares of Biocon settled 4.97 per cent higher at Rs 298.75 apiece on the BSE.

Also Read | Motilal Nehru Death Anniversary 2024 Date: Know All About the Day That Marks the Punyatithi of One of the Great Leaders of India.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)